200 related articles for article (PubMed ID: 34466656)
1. Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity.
Volpatti LR; Wallace RP; Cao S; Raczy MM; Wang R; Gray LT; Alpar AT; Briquez PS; Mitrousis N; Marchell TM; Sasso MS; Nguyen M; Mansurov A; Budina E; Solanki A; Watkins EA; Schnorenberg MR; Tremain AC; Reda JW; Nicolaescu V; Furlong K; Dvorkin S; Yu SS; Manicassamy B; LaBelle JL; Tirrell MV; Randall G; Kwissa M; Swartz MA; Hubbell JA
ACS Cent Sci; 2021 Aug; 7(8):1368-1380. PubMed ID: 34466656
[TBL] [Abstract][Full Text] [Related]
2. Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
Volpatti LR; Wallace RP; Cao S; Raczy MM; Wang R; Gray LT; Alpar AT; Briquez PS; Mitrousis N; Marchell TM; Sasso MS; Nguyen M; Mansurov A; Budina E; Solanki A; Watkins EA; Schnorenberg MR; Tremain AC; Reda JW; Nicolaescu V; Furlong K; Dvorkin S; Yu SS; Manicassamy B; LaBelle JL; Tirrell MV; Randall G; Kwissa M; Swartz MA; Hubbell JA
bioRxiv; 2021 Apr; ():. PubMed ID: 33851166
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
[TBL] [Abstract][Full Text] [Related]
4. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
[TBL] [Abstract][Full Text] [Related]
6. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.
Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA
Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664
[TBL] [Abstract][Full Text] [Related]
7. Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2.
Lin G; Yan H; Sun J; Zhao J; Zhang Y
Mol Ther Nucleic Acids; 2023 Jun; 32():650-666. PubMed ID: 37151990
[TBL] [Abstract][Full Text] [Related]
8. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
10. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
14. Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.
Rodrigues-Jesus MJ; Teixeira de Pinho Favaro M; Venceslau-Carvalho AA; de Castro-Amarante MF; da Silva Almeida B; de Oliveira Silva M; Andreata-Santos R; Gomes Barbosa C; Brito SCM; Freitas-Junior LH; Boscardin SB; de Souza Ferreira LC
Nanomedicine; 2022 Sep; 45():102595. PubMed ID: 36031045
[TBL] [Abstract][Full Text] [Related]
15. Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.
Wahba MA; Mofed D; Ghareeb DA; Omran JI; Salem TZ
J Genet Eng Biotechnol; 2023 Feb; 21(1):16. PubMed ID: 36759349
[TBL] [Abstract][Full Text] [Related]
16. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
17. Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; Dâ Aquino AI; Pulendran B; Kim PS; Appel EA
bioRxiv; 2021 Aug; ():. PubMed ID: 33821276
[TBL] [Abstract][Full Text] [Related]
18. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
19. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Lan J; Deng Y; Chen H; Lu G; Wang W; Guo X; Lu Z; Gao GF; Tan W
PLoS One; 2014; 9(11):e112602. PubMed ID: 25405618
[TBL] [Abstract][Full Text] [Related]
20. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.
Wang J; Yin XG; Wen Y; Lu J; Zhang RY; Zhou SH; Liao CM; Wei HW; Guo J
J Med Chem; 2022 Feb; 65(4):3563-3574. PubMed ID: 35108485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
